DCB001 - our flagship project
Among the new family of antimicrobial compounds we discovered, DCB001 leads our main project : a new precision treatment against MRSA-led bacteremia and other Staphylococcus aureus-related infections.
New structural class
New chemical structure with a trichloroacetimidamide function
Narrow spectrum
Clinically Relevant Pathogens tested
No resistance
Single- (<10E-11) and Multiple-step (>40 passages) assays has been performed
New class of
antibiotic candidate
A new chemical class against Staphylococcus aureus - Trichloroacetimidamides (TriCA2)
Hundreds of new chemical structures have been generated to create an in-house library of new drug candidates. Among more than 300 of new synthetic derivatives (all ranging 250-350Da and respecting Lipinski criteria), only one candidate was found to inhibit bacterial growth. This new chemical structure with a trichloroacetimidamide function was faced to a first optimization round and, from more than 50 derivatives, we identified DCB001 to have the highest antibacterial activity.
Specific to
Staphylococcus aureus
A new generation of precision therapeutics against Staphylococcus aureus
This heat-map shows a reduced selection of the minimal inhibitory concentration (MIC) found upon screening of tens of pathogenic strains of clinically relevant pathogens. We found a particular specificity of DCB001’s activity against Staphylococcus aureus strains, which could be a clue of a reduced patient side-effects mainly on microbiota.
No resistance observed
Different assays on multiple strains showed a low-to-no resistance/mutation rate for DCB001
Single- and multiple step assays have been performed to uncover potential strains becoming resistant to DCB001. No colony has been isolated on the plate or liquid culture to be able to grow even at high concentration (10E10 bacteria) or multiple passages (>20 passages at under-MIC).
DCB001 is effective in vivo
DCB001 activity in vivo has been shown in both MSSA and MRSA bacteremia infection models (10E6 bacteria/animal). We can observe significant decrease of bacteremia in mice treated with DCB001 at 8 mg/kg at 48 hours. Both, Ampicillin and Vancomycin treatment groups had comparable effet on bacteremia levels to the ones observed in DCB001 treatment. These results show the high potential of DCB001 as an antibiotic candidate to treat severe infections caused by sensitive and MDR-MRSA strains. In addition, we have obtained great pharmacokinetic profile, with a moderate half-life, good stability and a low-moderate excretion and distribution rates.
Legal Notice © Copyright. All rights reserved.
Nous avons besoin de votre consentement pour charger les traductions
Nous utilisons un service tiers pour traduire le contenu du site web qui peut collecter des données sur votre activité. Veuillez consulter les détails dans la politique de confidentialité et accepter le service pour voir les traductions.